Last reviewed · How we verify
Placebo DPI
Placebo DPI is an inert formulation delivered via dry powder inhaler that produces no pharmacological effect.
Placebo DPI is an inert formulation delivered via dry powder inhaler that produces no pharmacological effect. Used for Clinical trial control / comparator product.
At a glance
| Generic name | Placebo DPI |
|---|---|
| Sponsor | Amphastar Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo product, it contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials or as a reference standard. It is administered through a dry powder inhaler (DPI) device to match the delivery route and patient experience of active respiratory medications without conferring therapeutic benefit.
Approved indications
- Clinical trial control / comparator product
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Corticosteroid Therapy in Pulmonary Sequelae of Covid-19 (PHASE1)
- A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PHASE3)
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis (PHASE1)
- Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy (PHASE2)
- A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) (PHASE3)
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants. (PHASE1)
- A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo DPI CI brief — competitive landscape report
- Placebo DPI updates RSS · CI watch RSS
- Amphastar Pharmaceuticals, Inc. portfolio CI